Li Yi, Liu Ao, Wang Xin, Guo Longxiang, Li Yuanlin, Liu Defeng, Liu Xiuli, Li Zhichao, Li Minghuan
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Department of Radiation Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Cancer Med. 2025 Feb;14(4):e70638. doi: 10.1002/cam4.70638.
In patients with locally advanced cervical cancer (LACC) undergoing concurrent chemoradiotherapy (CCRT), the high incidence of radiation-induced lymphopenia significantly affects prognosis. There are significant variations in lymphocyte count (ALC) recovery patterns among patients, and their impact on prognosis remains unclear. This study aims to quantify the lymphocyte recovery patterns by the lymphocyte recovery index (LRI) and evaluate its prognostic value.
This study reviewed patients with LACC who had ALCs available within 6 months post-CCRT. Lymphopenia was graded using CTCAE 5.0, and lymphocyte recovery patterns were quantified using LRI (the ratio of ALCs at 6 months post-treatment to baseline ALCs). Cox regression analysis was conducted to assess the correlation between LRI, other clinical factors, and survival. The dose-volume of bone marrow (BM) following pelvic radiotherapy was collected, and measurements of spleen standardized uptake value (SUV) and spleen-to-liver SUVmax ratio (SLR) were obtained from pre-treatment 18F-FDG PET/CT. Logistic regression analysis was used to identify independent risk factors for LRI.
A total of 180 patients were included retrospectively. During CCRT, 53 patients (29.4%) experienced G4 lymphopenia. The median LRI was 53.4% (range 13.2%-159.4%). Multivariable analysis revealed that LRI, G4 lymphopenia, and FIGO stage were associated with progression-free survival (PFS) and overall survival (OS). Subgroup analysis revealed that the degree of lymphopenia (G4 and G1-3) did not affect the correlation between LRI and PFS (P: 0.001 and 0.011) or OS (P: 0.003 and 0.043). Regarding FIGO stage, the impact of LRI on PFS (p < 0.001) and OS (p < 0.001) was primarily observed in patients with FIGO stage > II. Logistic analysis identified BM-V10 > 96.0% and SLR > 0.90 as independent risk factors for LRI.
In patients with LACC after CCRT, the LRI is associated with prognosis. Splenic metabolism and BM irradiation are associated with lymphocyte recovery.
在接受同步放化疗(CCRT)的局部晚期宫颈癌(LACC)患者中,放射性淋巴细胞减少的高发生率显著影响预后。患者之间淋巴细胞计数(ALC)恢复模式存在显著差异,其对预后的影响尚不清楚。本研究旨在通过淋巴细胞恢复指数(LRI)量化淋巴细胞恢复模式,并评估其预后价值。
本研究回顾了CCRT后6个月内有可用ALC的LACC患者。使用CTCAE 5.0对淋巴细胞减少进行分级,并使用LRI(治疗后6个月时的ALC与基线ALC的比值)量化淋巴细胞恢复模式。进行Cox回归分析以评估LRI、其他临床因素与生存之间的相关性。收集盆腔放疗后骨髓(BM)的剂量体积,并从治疗前18F-FDG PET/CT获得脾脏标准化摄取值(SUV)和脾脏与肝脏SUVmax比值(SLR)的测量值。使用逻辑回归分析确定LRI的独立危险因素。
共纳入180例患者进行回顾性分析。在CCRT期间,53例患者(29.4%)出现4级淋巴细胞减少。LRI的中位数为53.4%(范围13.2%-159.4%)。多变量分析显示,LRI、4级淋巴细胞减少和国际妇产科联盟(FIGO)分期与无进展生存期(PFS)和总生存期(OS)相关。亚组分析显示,淋巴细胞减少程度(4级和1-3级)不影响LRI与PFS(P值分别为0.001和0.011)或OS(P值分别为0.003和0.043)之间的相关性。关于FIGO分期,LRI对PFS(p<0.001)和OS(p<0.001)的影响主要在FIGO分期>II期的患者中观察到。逻辑分析确定BM-V10>96.0%和SLR>0.90为LRI的独立危险因素。
在CCRT后的LACC患者中,LRI与预后相关。脾脏代谢和BM照射与淋巴细胞恢复相关。